title: Troponin I serum concentration: a new marker of left ventricular hypertrophy in patients with essential hypertension.
abstract: BACKGROUND
  Troponin I, a specific cardiac muscle protein, has proven to be very helpful in detecting myocardial damage in ischemic heart disease. In order to assess if this laboratory test may also characterize some hypertensive subjects with proven cardiac damage, we compared troponin I serum concentrations of a group of patients affected by systemic hypertension and left ventricular hypertrophy (LVH) with troponin I serum concentrations of hypertensive patients without LVH and with normal controls.
  
  
  METHODS
  Of 100 hypertensive patients consecutively enrolled in the study, 27 had an increased left ventricular mass by M-mode/two-dimensional echocardiographic examination. Of these, 4 were excluded for significant Holter ST-segment modification. Troponin I was measured in the remaining 23, in 23 age- and sex-matched hypertensive patients with normal left ventricular mass and in 23 normal controls.
  
  
  RESULTS
  Troponin I serum concentration was higher than the upper limit of the normal values (0.5 ng/mi) in 12 of the 23 hypertensives with LVH. On the contrary, all hypertensives without LVH and all normal controls had troponin I serum concentration below the upper limit of the normal values. Consequently, the mean troponin I serum value was significantly higher in the group of hypertensive patients with LVH than in the group of patients without LVH (0.88 +/- 0.93 vs 0.27 +/- 0.08 ng/ml, p = 0.002) and in normal controls (0.88 +/- 0.93 vs 0.22 +/- 0.04 ng/ml, p = 0.0001).
  
  
  CONCLUSIONS
  Our data indicate that a significant proportion of patients affected by essential hypertension with LVH have slightly elevated troponin I serum concentrations. This test seems to identify two subgroups of hypertensive subjects with LVH, and, considering that troponin I is a marker of myocardial damage, higher serum values probably indicate a more important cardiac involvement in the setting of a hypertensive disease.
authors.affiliation: Istituto di Patologia Medica, Catholic University of the Sacred Heart, Rome, Italy. pizpalu@tin.it
authors.forename: M
authors.initials: M
authors.lastname: Siciliano
authors.forename: M
authors.initials: M
authors.lastname: Mettimano
authors.forename: A
authors.initials: A
authors.lastname: Dondolini-Poli
authors.forename: S
authors.initials: S
authors.lastname: Ballarin
authors.forename: A
authors.initials: A
authors.lastname: Migneco
authors.forename: R
authors.initials: R
authors.lastname: Annese
authors.forename: L
authors.initials: L
authors.lastname: Fazzari
authors.forename: P
authors.initials: P
authors.lastname: Fedeli
authors.forename: M R
authors.initials: MR
authors.lastname: Montebelli
authors.forename: C
authors.initials: C
authors.lastname: Zuppi
authors.forename: L
authors.initials: L
authors.lastname: Savi
mesh_terms: D000328:Adult; D000368:Aged; D015415:Biomarkers; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis*; D017379:Hypertrophy, Left Ventricular / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D019210:Troponin I / Q000097:blood*
chemical_list: D015415:Biomarkers; D019210:Troponin I